NeoVentures Biotechnology Europe has joined NVIDIA Inception, a program designed to help startups evolve faster through cutting-edge technology and access to the latest technical resources from NVIDIA.

At NVB Europe, we’ve developed the Aptamarker Platform, a powerful, next-generation approach to High-Plex proteomics. Unlike traditional methods, this platform applies 268 million probes to every sample. As a result, we can comprehensively profile the entire protein landscape. This unmatched depth enables the identification of biomarkers related to disease stage, relapse versus remission, treatment response, and the risk of adverse side effects.

To fully unlock the value of this deep dataset, we’ve strategically integrated artificial intelligence at the core of our analysis. Consequently, we are able to transform complex molecular signals into clear, actionable insights. These insights are essential for driving the advancement of precision and personalized medicine.

Furthermore, with the support of NVIDIA’s cutting-edge computational tools, we are significantly expanding our ability to model probe–protein interactions at the tertiary structural level. Thanks to this advancement, we can move beyond detecting whole proteins and begin identifying epitopes, specific regions within proteins, as highly predictive markers of disease progression or therapeutic response.

Moreover, as a proud member of the NVIDIA Inception program, and through our ongoing use of NVIDIA Cloud, we are well-positioned to accelerate therapeutic discovery. In turn, this collaboration is helping us deepen our understanding of disease mechanisms and establish a robust foundation for a new era of proactive, personalized healthcare.